Botswana was warned last week by a UN Committee that trade agreements should not undermine Botswana’s ability to ensure access to affordable treatment for children or other people with HIV/AIDS.
Twenty leading medical and legal experts, and seven peak health and community services organisations, will send today an open letter to John Howard and Mark Latham demanding changes to the free trade agreement with the US before the agreement is ratified in late October.
US Trade Representative Robert Zoellick’s warning to Australia that an amended free-trade agreement might conflict with the letter and spirit of the original agreement was prompted by bullying from the American pharmaceuticals industry, according to a US trade adviser.
Tariffs on agricultural products and definitions of intellectual property rights, particularly for pharmaceuticals, are shaping up as the most contentious issues in the free trade negotiations between the United States and three Andean nations, Colombia, Ecuador, and Peru.
The Colombian Germán Velásquez says that it was unfair for the US to veto the Argentine advisor Carlos Correa. He claims that poor countries must continue to have access to cheap medicines even if there are trade treaties. His request is that the Doha agreement is respected.
Australia’s ratification of a free trade agreement with the United States has sparked warnings that it represents a major win for the U.S. drug industry in blocking generic manufacturers and undermining the country’s internationally acclaimed system for lowering pharmaceutical prices.
The funny thing about the free trade agreement with the United States is that Australians and Americans see it as being about completely different things. Australia’s businesspeople see it as about eliminating the barriers to exports and imports between the two countries, which they regard as a good thing.
Kerryn Williams spoke to David Henry, clinical pharmacology professor at Newcastle University and former Pharmaceutical Benefits Advisory Committee member, about how the proposed US-Australia Free Trade Agreement will undermine the Pharmaceutical Benefits Scheme, and increase the price of medicine.
Re: Excluding Intellectual Property from negotiations over
a U.S.- Southern African Customs Union (SACU) Free Trade Agreement
Developing countries have entered into a large number of bilateral investment treaties (BITs) as well as free trade agreements (FTAs) that include explicit obligations for the protection of intellectual property rights as "investments".
A long-awaited Australia-US free trade agreement (FTA) hit a new snag in Canberra, just hours after US President George W. Bush reaffirmed Washington’s commitment to a pact he called "a milestone in the history of our alliance".
Welcome to the brave new world of “Free” Trade. This is a world that extends beyond the World Trade Organisation. This may be difficult to comprehend, but the fact of the matter is that global capital, led by the US government, seeks more and more to tread where even the WTO did not.
If Howard and Bush’s so-called ’free trade’ deal is confirmed by the Australian parliament and senate (WHICH CAN ONLY HAPPEN IF THE ALP VOTES WITH THE GOVERNMENT), genetically engineered crops and foods will be forced down our throats and onto our farms, and our hopes for GE-free Australia will end!!
The government lied when it said it would exclude medicines from the list of products included under the prospective freetrade agreement between Thailand and the United States, a seminar was told yesterday.
The Medical Journal of Australia, published by the Australian Medical Association, this week carries two articles claiming the free trade agreement (FTA) will undermine the Pharmaceutical Benefits Scheme (PBS).
Bilateral trade treaties have hit stormy waters in recent weeks, drawing criticism from French President Jacques Chirac, a leading world economist and human rights groups alike.
The reason for President Museveni’s renewed vigour to support US ideologies in the battle against HIV/Aids is becoming clearer after Bangkok, Thailand.
As public-health groups urge wider use of generic drugs to lower the cost of treating AIDS and other diseases in developing countries, U.S. trade negotiators — prodded by the drug industry — are taking the opposite stance in new trade pacts, seeking to strengthen protections for costlier brand-name drugs.
The US and France clashed on Tuesday over allegations by President Jacques Chirac that Washington was seeking to use bilateral trade agreements to reduce developing countries’ access to cheap medicines for diseases such as HIV/Aids.
As the United States and Peru negotiate a bilateral trade pact, a United Nations human rights expert has urged them to ensure any agreement includes public health safeguards so that essential drugs do not become unaffordable for millions of Peruvians.